Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: NOD2 agonists promote immune checkpoint inhibitor therapy

PROVIDER: PRJNA891889 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21979851.fastq.gz	Fastqsanger.gz
	SRR21979852.fastq.gz	Fastqsanger.gz
	SRR21967092.fastq.gz	Fastqsanger.gz
	SRR21967093.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

Project description:MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma

| PRJNA764915 | ENA

Project description:Intra-dendritic cell microbiome upon immune checkpoint inhibitor therapy (ICT)

| PRJNA886832 | ENA

Project description:Fluctuations in gut microbiome composition during immune checkpoint inhibitor therapy

| PRJNA919051 | ENA

TLR2/6 agonists and IFNgamma induce CXCL10 from melanoma

Project description:Clinical approaches to treat advanced melanoma include immune therapies, whose benefits depend on tumor-reactive T-cells to infiltrate metastases. However, most tumors lack significant immune infiltration prior to therapy, and some immune therapies are hindered by a persistent lack of immune cell infiltration. CXCL10 has been implicated as a critical chemokine supporting T-cell migration into tumors; thus agents that induce CXCL10 in tumors may improve patient responses to systemic immune therapy. We find that melanoma cells treated with TLR2/6 agonists (MALP-2 or FSL-1) and interferon-gamma (IFNgamma) upregulate CXCL10 production, when compared to IFNgamma treatment alone or no treatment. Gene profiling of melanoma cells lines treated with TLR2/6 agonists and IFNgamma demonstrate that a selective profile of genes are induced which may be favorable for promoting immune cell infiltration of tumors. TLR2 and TLR6 are widely expressed on human melanoma cells, and treatment of melanoma cells with TLR2/6 agonists and IFNgamma does not hinder melanoma cell apoptosis or promote proliferation. Furthermore, melanoma cells from surgically resected patient tumors upregulate CXCL10 production after treatment with TLR2/6 agonists and IFNgamma when compared to treatment with either agent alone. Collectively, these data identify TLR2/6 agonists and IFNgamma as a novel target for promoting CXCL10 production directly from melanoma cells. Samples from four human melanoma cell lines, VMM1 (n=6), DM13 (n=6), DM93 (n=6) and VMM39 (n=6), were treated with media alone, MALP-2 (TLR2/6 agonist), FSL-1 (TLR2/6 agonist), IFNgamma alone, MALP-2 and IFNgamma, or FSL-1 and IFNgamma.

2015-11-22 | E-GEOD-64506 | biostudies-arrayexpress

Immune checkpoint inhibitor-induced colitis

Project description:Immune checkpoint inhibitor-induced colitis

| PRJNA857579 | ENA

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and dependent on IL23 and IFNgamma

Project description:Immune checkpoint inhibitor-induced colitis

| PRJEB65719 | ENA

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitor therapy

Project description:Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitor therapy

| PRJNA725159 | ENA

Association of tumor burden with the efficacy of PD-(L)1 inhibitors for treatment-naive advanced non-small-cell lung cancer

Project description:A high tumor mutation was associated with a poor outcome of immune checkpoint inhibitor therapy for advanced NSCLC as a result of immunosuppressive phenotypes.

2023-12-18 | GSE250262 | GEO

RNA-seq of pancreatic mouse tumor cell lines

Project description:KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib. Using bulk and single-cell RNA sequencing and immunophenotyping, we show that the combination therapy reprograms the immunosuppressive microenvironment and primes cytotoxic and memory T cells to infiltrate the tumors, thereby sensitizing mesenchymal PDAC to PD-L1 inhibition.

2021-11-29 | E-MTAB-11187 | biostudies-arrayexpress

Single cell RNA-seq of pancreatic mouse tumors upon treatment

Project description:KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi- kinase inhibitor nintedanib. Using single cell RNA sequencing and immunophenotyping, we show that the combination therapy reprograms the immunosuppressive microenvironment and primes cytotoxic and memory T cells to infiltrate the tumors, thereby sensitizing mesenchymal PDAC to PD-L1 inhibition.

2021-11-13 | E-MTAB-9954 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data